Narcolepsy clinical trials at UCSF
2 in progress, 1 open to eligible people
ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
open to eligible people ages 18-70
The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.
San Francisco, California and other locations
HBS-301 in Participants With Narcolepsy
Sorry, not currently recruiting here
This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness/wakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.
San Francisco, California and other locations
Our lead scientists for Narcolepsy research studies include Andrew Krystal.
Last updated: